lilly glp 1 injection releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly's new weight-loss pill,

Two vials for Phase 2 is manageable

Emma Boyd , Surya Gourneni, Emily Wood, Francesca Bagnato, and Vasiliki Ikonomidou

The warning specifically contraindicates Zepbound in patients with: Personal history of medullary thyroid carcinoma (MTC) Family history of MTC Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) , a hereditary condition that significantly increases MTC risk MEN 2 is an inherited disorder caused by mutations in the RET proto-oncogene, leading to increased susceptibility to MTC, pheochromocytoma, and parathyroid tumors

Benefits include: Accurate dosing Ease of use Reduced discomfort Improved consistency DOSAGE RECOMMENDATIONS Use strictly according to manufacturer specifications

Randomized trials in Graves disease have shown slight biochemical increases in thyroid hormone levels, but no discernible decrease in relapse rates or long-term clinical benefit

Cuccurazzu B, Bortolotto V, Valente MM, Ubezio F, Koverech A, Canonico PL, et al